Telomerase Activity In Preleukemia And Acute Myelogenous Leukemia

References

• Hotta T. Clonality in hematopoietic disorders. International Journal of Hematology 1997; 66(4)403
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Bi S., Venugopal P., Raza A. Cytokines, molecular biological abnormalities, and acute myelogenous leukemia. Leukemia Research 1997; 21(4)299–-312
   PubMed Web of Science ®Google Scholar
• Nilsson S. K., Dooner M. S., Tiarks C. Y., Weier H. U., Quesenberry P. J. Potential and distribution of transplanted hematopoietic stem cells in a nonablated mouse model. Blood 1997; 89: 4013
   PubMed Web of Science ®Google Scholar
• Luban NL. Hemolytic disease of the newborn: progenitor cells and late effects. New England Journal Medicine 1998; 19(12)830, 338:
   Web of Science ®Google Scholar
• Preisler H D. Fitness landscapes and the myeloid leukemias. Leukemia Research. 1999; 3(2)167–176
   Web of Science ®Google Scholar
• Vaziri H., Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Current Biology. 1998; 8(5)279–82
   PubMed Web of Science ®Google Scholar
• Beattie T. L., Zhou W., Robinson M. O., Harrington L. Reconstitution of human telomerase activity in vitro. Current Biology 1998; 29(3)177, 8:
   Web of Science ®Google Scholar
• Kataoka H., Tahara H., Watanabe T., Sugawara M., Ide T, Goto M., Furuichi Y., Sugimoto M. Immortalization of immunologically committed Epstein-Barr virus-transformed human B-lymphoblastoid cell lines accompanied by a strong telomerase activity. Differentia-tion 1997; 62(4)203
   PubMed Web of Science ®Google Scholar
• Katoh M., Katoh M, Kameyama M, Kugoh H., Shimizu M., Oshimura M. A repressor function for telomerase activity in telomerase-negative immortal cells. Molecular Carcinogenesis 1998; 21(1)17
   PubMed Web of Science ®Google Scholar
• Seol J. G., Kim E. S., Park W. H., Jung C. W., Kim B. K., Lee Y. Y. Telomerase activity in acute myelogenous leukaemia: clinical and biological implications. British Journal of Haematology 1998; 100(1)156, 1998:
   PubMed Web of Science ®Google Scholar
• Ishikawa F. Telomere crisis in leukemia. International Journal Hematology 1997; 65(4)355
   PubMed Web of Science ®Google Scholar
• Norrback K. F., Roos G. Telomeres and telomerase in normal and malignant hematopoietic cells. European Journal of Cancer 1997; 33(5)774
   PubMed Web of Science ®Google Scholar
• Ohyashiki K., Ohyashiki J. H. Telomere dynamics and cytogenetic changes in human hematologic neopla-sias: a working hypothesis. Cancer Genetics & Cytogenetics 1997; 94(1)67
   PubMed Web of Science ®Google Scholar
• Counter CM., Gupta J., Harlwy C. B., Leber B., Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995; 85: 2315–2320
   PubMed Web of Science ®Google Scholar
• Zhang W., Piatyszek M. A., Kobayashi T, Estey E., Andreeff M., Deisseroth A.B., Wright W. E., Shay J. W. Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Clinical Cancer Research 1996; 2: 799–803
   PubMed Web of Science ®Google Scholar
• Shay J. W., Werbin H., Wright W. E. Telomeres and telomerase in human leukemias. Leukemia 1996; 10: 1255–1261
   PubMed Web of Science ®Google Scholar
• Ohyashiki J. H., Ohyashiki K, Iwama H, Hayashi S, Toyama K, Sahy J. W. Clinical implications of telomerase activity levels in acute leukemia. Clinical Cancer Research 1997; 3: 619–625
   PubMed Web of Science ®Google Scholar
• Carter G., Hughes DC, Clark RE., McCormick F., Jacobs A., Whittaker JA., Padua RA. RAS mutations in patients following cytotoxic therapy for lymphoma. Onco-gene. 1990; 5(3)411–6
   Google Scholar
• Baker A, Cachia P, Ridge S, McGlynn H, Clarke R, Whittaker J, Jacobs A, Padua R A. FMS mutations in patients following cytotoxic therapy for lymphoma. Leukemia Research. 1995; 19(5)309–18
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Li B., Yang J., Horvath E., Raza A., Loew J., Gregory S., Hsu W-T., Showel J., Adler S., Bi S. The premyelodysplastic state and the secondary hematologic disorders. Acute Leukemias VII Symposium, Published in Acute Leukemias VII, Experimental Approaches and Novel therapies, W. Hiddemann, T Buchner, B. Worman, J. Ritter, U. Creutzig, M. Keating, W. Plunkett. Springer Verlag Berlin Heidelberg. 1998; 102–107
   Google Scholar
• Karp J E. Molecular pathogenesis and targets for therapy in myelodysplastic syndrome (MDS) and MDS-related leukemias. Current Opinion in Oncology. 1998; 10(l)3–9
   PubMedGoogle Scholar
• Preisler H. D., Raza A., Barcos M., Azarnia N., Larson R., Wlaker I., Browman M., Grunwald H., Darrigo P., Doe-blin T., Bloom M., Stein A., Logue G., Goldberg J., Kirsh-ner J., Gottlieb A., Bennett J. High dose cytosine arabinoside as the initial treatment of poor risk patients with acute nonlymphocytic leukemia: A Leukemia Intergroup Study. Journal of Clinical Oncology 1987; 5(l)75–82
   PubMedGoogle Scholar
• Raza A., Preisler H. D., Day R., Yasin Z., White L. M., Lykins J., Barcos M., Bennett J., Browman G., Goldberg J., Grunwald H., Larson R., Vogler R. Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics. A Leukemia Intergroup Study. Blood 1990; 76(11)2191–-2197
   Google Scholar
• Gown A. M., Jiang J. J., Matles H., Skelly M., Goodpaster T, Cass L., Reshatof M., Spaulding D., Coltrera M. D. Validation of the S-phase specificity of histone (H3) in situ hybridization in normal and malignant cells. Journal of Histochemistry & Cytochemistry 1996; 44(3)22 1
   Google Scholar
• Preisler H. D., Kotelnikov V, Cass L., Coon J. D. Accuracy of histone H3 mRNA in situ hybridization for the assessment of cell proliferation in human tissues. Clinical Cancer Research 1997; 3: 669–675
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Kauffman S. 1998, A proposal regarding the mechanism which underlies lineage choice during hematopoietic differentiation. In press, Leukemia Research
   Google Scholar
• Bryan T. M., Englezou A, Dalla-Pozza L., Dunham M. A., Reddel R. R. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nature Medecine 1997; 3(11)1271
   PubMed Web of Science ®Google Scholar
• Woodring E. W., Shay J, Mieczyslaw A. P. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Research. 1995; 23(18)3794
   PubMed Web of Science ®Google Scholar
• Gale RE., Bunch C., Moir D.J., Patterson A. H., Linch D. C. Demonstration of developing myelodyspla-sia/acute myeloid leukaemia in haematologically normal patients after high-dose chemotherapy and autologous bone marrow transplanation using x-chromosome inactivation patterns. British Journal of Haematology 1996; 93: 53
   PubMed Web of Science ®Google Scholar
• Busque L, Mio R, Mattioli J, Brais E, Blais N, Lalonde Y, Maragh M, Gilliland D G. Nonrandom X-inactivation patterns in normal females: Lyonization ratios vary with age. Blood. 1996; 88(1)59–65
   PubMed Web of Science ®Google Scholar
• Ohyashiki K., Ohyashiki J.H., Iwama H., Hayashi S., Shay J. W., Toyama K. Telomerase reactivation in leukemia cells. International Journal of Oncology 1996; 8: 417
   PubMed Web of Science ®Google Scholar
• Feng J., Funk W. D., Wang S. S., Weinrich S. L., Avilion A. A., Chiu C. P., Adams R. R., Chang E., Allsopp R. C., Yu J., Le S., West M. D., Harle C. B., Andrews W. H., Greider C. W., Villeponteau B. The RNA component of human telomerase. Science 1995; 269: 1236
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Devemy E., Tao M., Li B., Yang J., Chopra H., Goyal R., Venugopal P. Alteration of cytok-ine production by AML cells in vivo in patients. Proceeding of American Association of Cancer Research 1997; 39: 153, Abstr #1047
   Google Scholar
• Preisler H. D., Li B., Yang J., Huang R. W., Devemy E., Venugopal P., Tao M., Chopra H., Gregory S. A., Adler S., Sivaraman S., Toofanfard P., Jajeh A., Galvez A., Robin E. 1998, Suppression of telomerase activity, cytokine mRNA levels, and proliferation of acute myelogenous leukemia cells in vivo in patients. In press. Clinical Cancer Research
   Google Scholar